SCHEMBL1435337

SCHEMBL1435337

CC(=O)c1cccc(C=C/C=N/Nc2nc(-c3ccc(C(F)(F)F)cc3)cs2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.56
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
ALDH1A1 P00352 4/20 0.56
GAA P10253 4/20 0.56
POLB P06746 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GSTO1 P78417 1/20 0.46
ALOX5 P09917 1/20 0.46
KDM4E B2RXH2 3/20 0.45
MAPK1 P28482 2/20 0.45
HDAC4 P56524 1/20 0.44
MEF2D Q14814 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PTGS2 P35354 1/20 0.44
LMNA P02545 2/20 0.43
RECQL P46063 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435339 1.00 MAPT (0.56) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435335 1.00 MAPT (0.56) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1436308 0.91 MAPT (0.53) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1436534 0.91 MAPT (0.53) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435455 0.91 MAPT (0.53) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435458 0.91 MAPT (0.53) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435415 0.86 GAA (0.58) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435309 0.86 GAA (0.58) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435310 0.86 GAA (0.58) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL1435385 0.84 GAA (0.74) MAPTMEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1898908-B1 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT TROPHOS (FR) 2011-03-30 EP claimed
US-20090203747-A1 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE TROPHOS PARC SCIENTIFIQUE LUMINY (FR) 2009-08-13 US claimed
EP-1898908-A2 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT Trophos (FR) 2008-03-19 EP claimed
WO-2007003767-A2 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE TROPHOS (FR) 2007-01-11 WO claimed
EP-1898908-B1 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT TROPHOS (FR) 2011-03-30 EP disclosed
US-20090203747-A1 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE TROPHOS PARC SCIENTIFIQUE LUMINY (FR) 2009-08-13 US disclosed
EP-1898908-A2 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICAMENT Trophos (FR) 2008-03-19 EP disclosed
WO-2007003767-A2 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE TROPHOS (FR) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203747-A1 NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE NLN, NQO1, APP MAPT 31/4885MEN1 1055/4885KMT2A 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.